Five Year Follow-Up of a Phase 2 Clinical Trial to Induce Tolerance in Mismatched Living Donor Renal Transplant Recipients.

Leventhal, J. R.; Abecassis, Michael; Miller, Jeremy J.; Gallon, Lorenzo; Galvin, John P.; Mehta, Jyotsna; Ravindra, Kadiyala V.; Tollerud, David J.; Elliot, M.; Ildstad, S.

doi:10.1097/00007890-201407151-00689

Cited by 7 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients who became tolerant had over 300 genes uniquely up‐ or downregulated—not in the B cell family as in prior reports —and had greater Treg increases over time. The second presentation reported 7‐year follow‐up data of combined facilitator cell therapy and living donor kidney transplantation in HLA‐mismatched recipients , extending the results from the initial report . This demonstrated a high percentage achieving full tolerance and hematopoietic chimerism with a low incidence of graft‐versus‐host disease.…”

Section: Clinical Sciencementioning

confidence: 71%

What’s Hot, What’s New From the 2016 American Transplant Congress

Levitsky

Gill

2016

American Journal of Transplantation

View full text Add to dashboard Cite

From June 11-15, 2016 the American Transplant Congress, the joint meeting of the American Society of Transplantation and the American Society of Transplant Surgeons, held its annual meeting in Boston, MA. The meeting, attended by 5200 registrants, included pre-meeting conferences, focused topic sessions, and hundreds of high-quality presentations from the transplant field. This meeting report highlights key findings from specific basic science, translational, and clinical research presentations deemed to have notable impact in thematic areas. In particular, there were a number of transformative studies indicating important advances in the understanding of alloimmunity, chronic rejection, tolerance, and organ-specific outcomes. Many of these results are discussed in the context of the published literature to showcase rapid advances in the transplant field.

show abstract

Section: Clinical Sciencementioning

confidence: 71%

What’s Hot, What’s New From the 2016 American Transplant Congress

Levitsky

Gill

2016

American Journal of Transplantation

View full text Add to dashboard Cite

show abstract

“…However, notably, the limitation of this full donor chimerism approach was the development of severe graft-versus-host disease (GVHD), which resulted in a patient death under these protocols. 42 In another tolerance study by these authors, HLA-matched kidney transplantation was performed without myeloablative conditioning, but with repeated donor hematopoietic cell infusions during the first 9 months after transplantation. 43 Five of 10 patients developed tolerance as evidenced by normal biopsies 1 year after withdrawal of immunosuppression.…”

Section: Tolerance Induction Strategies In Transplantationmentioning

confidence: 99%

Contemporary Strategies and Barriers to Transplantation Tolerance

et al. 2018

View full text Add to dashboard Cite

The purpose of this review is to discuss immunologic tolerance as it applies to solid organ transplantation and to identify barriers that hinder the achievement of this long-term goal. First, the definition of tolerance and an introduction of mechanisms by which tolerance exists or can be achieved will be discussed. Next, a review of contemporary attempts at achieving transplant tolerance will be described. Finally, a discussion of the humoral barriers to transplantation tolerance and potential ways to overcome these barriers will be presented.

show abstract

“…Two of 30 subjects lost their allograft due to infectious complications. Although the incidence of GVHD was reduced significantly, even in HLA‐mismatched transplantation, two of 30 patients developed GVHD and one was dead . The state of full chimerism has been considered immuno‐incompetent , and two serious infectious complications that resulted in graft loss have been reported.…”

Section: Clinical Trialsmentioning

confidence: 99%

Chimerism-based tolerance in organ transplantation: preclinical and clinical studies

Oura

Cosimi

Kawai

2017

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SummaryInduction of allograft tolerance has been considered the ultimate goal in organ transplantation. Although numerous protocols to induce allograft tolerance have been reported in mice, a chimerism-based approach through donor haematopoietic stem cell transplantation has been the only approach to date that induced allograft tolerance reproducibly following kidney transplantation in man. Renal allograft tolerance has been achieved by induction of either transient mixed chimerism or persistent full donor chimerism. Although the risk of rejection may be low in tolerance achieved via durable full donor chimerism, the development of graft-versus-host disease (GVHD) has limited the wider clinical application of this approach. In contrast, tolerance induced by transient mixed chimerism has not been associated with GVHD, but the risk of allograft rejection is more difficult to predict after the disappearance of haematopoietic chimerism. Current efforts are directed towards the development of more clinically feasible and reliable approaches to induce more durable mixed chimerism in order to widen the clinical applicability of these treatment regimens.

show abstract

Five Year Follow-Up of a Phase 2 Clinical Trial to Induce Tolerance in Mismatched Living Donor Renal Transplant Recipients.

Cited by 7 publications

References 0 publications

What’s Hot, What’s New From the 2016 American Transplant Congress

What’s Hot, What’s New From the 2016 American Transplant Congress

Contemporary Strategies and Barriers to Transplantation Tolerance

Chimerism-based tolerance in organ transplantation: preclinical and clinical studies

Contact Info

Product

Resources

About